Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA962)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 March 2024
Ovarian cancer: identifying and managing familial and genetic risk (NG241)Product type:GuidanceProgramme:NICE guidelinePublished: 21 March 2024
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer (TA946)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 January 2024
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (Review of TA611) [ID4069]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 12 June 2024
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 21 August 2024
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID6129]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer ID6442Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC